



O P E
SEP 21 2001
U.S. PATENT AND TRADEMARK OFFICE

Page 1 of 1

09/17/01

0300

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/026,106	12/21/2001	Jean-Christophe Renaud	LUD 5752 DIV JEL/NDH (101)

CONFIRMATION NO. 7513

24972
FULBRIGHT & JAWORSKI, LLP
666 FIFTH AVE
NEW YORK, NY 10103-3198

FORMALITIES LETTER



OC00000008787878

Date Mailed: 09/16/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

RTE
Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY

2001 SEP 19 A 10:01
FULBRIGHT & JAWORSKI, LLP
NEW YORK OFFICE

DOCKET DEPT.
RECEIVED



14

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via first class mail in an envelope addressed to the U.S. PTO, Box: Sequence, P.O. Box 2327, Arlington, VA 22202 on September 25, 2002.

Fulbright & Jaworski L.L.P.

LUD 5752 DIV JEL/NDH (10109097)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Jean-Christophe Renauld, et al.
Serial No : 10/026,106
Filed : December 21, 2001
For : ISOLATED CYTOKINE RECEPTOR LICR-2
Art Unit : UNKNOWN
Examiner : UNKNOWN

September 25, 2002

U.S. Patent and Trademark Office
Box: Sequence
P.O. Box 2327
Arlington, VA 22202

**LETTER RE:
NOTICE TO COMPLY**

SIR:

Responsive to the Notice of September 16, 2002, a copy of which is attached, please replace the current paper copy and computer readable forms of sequence information with the attached.

The undersigned hereby declares that, to the best of his knowledge, the paper copy and computer readable forms of sequence information are identical to each other and to information set forth in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

Norman D. Hanson, Esq.
Registration No. 30,946